© 2003 by Oxford University Press
© 2003 Oxford University Press
CORRESPONDENCE |
RESPONSE: Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer
On Behalf of the EORTCACTION Collaborators
Affiliations of authors: J. B. Trimbos, Leiden University Medical Center, Leiden, The Netherlands; I. Vergote, University Hospitals, Leuven, Belgium.
Correspondence to: J. Baptist Trimbos, MD, Ph.D., Department of Gynecology, Leiden University Medical Center, POB 9600, 2300 RC, Leiden, The Netherlands (e-mail: J.B.M.Z.Trimbos@lumc.nl).
| The first 10% of the full text of this article appears below. |
We thank Dr. Green for his compliments regarding the publication of the European Organisation for Research and Treatment of Cancer (EORTC)Adjuvant ChemoTherapy In Ovarian Neoplasm (ACTION) trial (1). Nevertheless, there are a number of comments with which we disagree.
Dr. Green supports the notion that the benefit of adjuvant chemotherapy is important enough to influence clinical decision making based on the overall and recurrence-free survival results of the combined analysis of the ACTION and